A delicate balance -pharmaceutical innovation and access

New England Journal of Medicine

Volumn 373, Issue 19, 2015, Pages 1799-1801

  Chin, William W ^a  

^a Pharmaceutical Researchers and Manufacturers of America   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; GENERIC DRUG;

CANCER RESEARCH; COMMERCIAL PHENOMENA; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE NEED; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HUMAN; LEADERSHIP; PATIENT DECISION MAKING; PHARMACY BENEFIT MANAGER; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM; UNITED STATES; DRUG DEVELOPMENT; ECONOMIC ASPECT; INVENTION; TRENDS;

DRUG COSTS; DRUG DISCOVERY; ECONOMIC COMPETITION; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; INVENTIONS; UNITED STATES;

EID: 84946595487     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1513227     Document Type: Review

References (5)

1. Altarum Institute. Center for Sustainable Health Spending data brief: A ten year projection of the prescription drug share of national health expenditures including nonretail. August 2015 (http://altarum.org/sites/default/files/uploaded-publication-files/Non-Retail%20Rx%20Forecast%20Data% 20Brief-with%20Addendum.pdf).
2. Fein AJ. OptumRx sails away with catamaran: Deal analysis and industry implications. Drug Channels Blog. March 31, 2015 (http://www.drugchannels.net/2015/03/optumrx -sails-Away-with-catamaran-deal.html).
3. Fein AJ. What Gilead's big hepatitis C discounts mean for biosimilar pricing. Drug Channels Blog. February 5, 2015 (http://www.drugchannels.net/2015/02/what-gileads -big-hepatitis-c-discounts.html#more).
4. Institute of Medicine. Delivering high quality cancer care: Charting a new course for a system in crisis. September 2013 (https://iom.nationalacademies.org/~/media/Files/Report%20Files/2013/Quality-Cancer-Care/qualitycancercare-rb.pdf).
5. NICE limits reimbursement for oncology products beyond EMA product labeling. Context Matters. May 2014 (http://www.phrma.org/sites/default/files/pdf/context -matters-nice-restrictiveness-oncology.pdf).